Abbott Laboratories has presented combined financials for its existing business and the now-separate AbbVie division which show that growth was driven again by the anti-inflammatory blockbuster Humira.
Fourth-quarter net income came in at $1.05 billion, down 34.9% due in part to costs connected to the split that has created AbbVie. Group sales increased 4.4% to $10.84 billion.
Revenues for proprietary pharmaceuticals, ie the part spun off into AbbVie, were up 7.4% to $5.14 billion. Over half of that came from Humira (adalimumab), which is approved for indications covering rheumatoid arthritis, Crohn’s disease and psoriasis; the blockbuster contributed $2.68 billion, a rise of 23.1%.
As for the company’s lipids franchise, TriCor (fenofibrate) and TriLipix (fenofibric acid) saw sales sink 50.7% to $269 million, hit by the loss of patent protection for the former. Niaspan (niacin) brought in $277 million, an increase of 7.4%.
Revenues from the HIV drug Kaletra (lopinavir/ritonavir) fell 13.4% to $250 million, while sales of the prostate cancer drug Lupron (leuprolide) dipped 1.6% to $211 million. Abbott also saw impressive growth for the hypothyroid medication Synthroid (levothyroxine), up 21.5% to $194 million, and its AndroGel testosterone replacement therapy, which climbed 39.6% to $373 million.
The company's nutritional products had sales of $1.72 billion, up 10.2%, while 'established pharmaceuticals', which includes sales of branded generics outside the USA, fell 2.4% to $1.35 billion. Turnover of vascular products, which includes heart stents, fell 8.1% to $760 million.